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Due to the many beneficial properties combined from both poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs)
and liposomes, lipid-PLGA hybrid NPs have been intensively studied as cancer drug delivery systems, bio-imaging
agent carriers, as well as antigen delivery vehicles. However, the impact of lipid composition on the performance of
lipid-PLGA hybrid NPs as a delivery system has not been well investigated. In this study, the influence of lipid
composition on the stability of the hybrid NPs and in vitro antigen release from NPs under different conditions
was examined. The uptake of hybrid NPs with various surface charges by dendritic cells (DCs) was carefully
studied. The results showed that PLGA NPs enveloped by a lipid shell with more positive surface charges could
improve the stability of the hybrid NPs, enable better controlled release of antigens encapsulated in PLGA NPs, as
well as enhance uptake of NPs by DC.
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Nanoparticles made from poly(lactic-co-glycolic acid)
(PLGA) or lipids have been used as drug delivery sys-
tems for many years. PLGA and liposome nanoparticles
(NPs) share some common merits, such as long circula-
tion time, biocompatibility, tunable size, and high drug
loading capacity [1,2]. Meanwhile, both PLGA and
liposome NPs have their own unique advantages. For
example, the degradation rate of PLGA NPs can be
flexibly controlled by adjusting the molar ratio between
glycolic acid and lactic acid [3], and substances with dis-
tinct physiochemical properties, including proteins, an-
ticancer drugs, nucleic acids, and even metal NPs, can
be easily incorporated into PLGA NPs. On the other
hand, liposome NPs can entrap hydrophobic drugs
between lipid layers while encapsulating hydrophilic
payloads in the aqueous core. In addition, the surface
chemistry of liposomes can be easily tuned to meet dif-
ferent requirements by simply adjusting the types or* Correspondence: chzhang2@vt.edu
1Department of Biological Systems Engineering, Virginia Tech, Blacksburg,
VA 24061, USA
Full list of author information is available at the end of the article
© 2014 Hu et al.; licensee Springer. This is an O
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in any medium, provided the original work is pconcentrations of lipids, and the inclusion of certain
lipid molecules with terminal reactive groups offers
great flexibility in conjugating target molecules with dif-
ferent chemical properties [4]. It is even possible to for-
mulate liposomes that are sensitive to a wide range of
external stimuli, such as heat, light, ultrasound, and pH,
to allow a highly controlled release of payloads [5].
However, PLGA and liposome NPs also have their own
limitations. For instance, the fabrication process for li-
posomes of accurate size is cumbersome [6], and they
are also plagued by storage instability and burst release
of the payload [7]. PLGA NPs, on the other hand, tend
to have a short half-life during circulation in vivo [7],
and the surface chemistry of PLGA NPs cannot be easily
modified. Therefore, it would be attractive to fabricate
lipid-PLGA hybrid NPs, which combine the desirable
characteristics of both liposome and PLGA NPs, mean-
while mitigating or even avoiding the aforementioned
limitations.
Indeed, in the past decade, lipid-PLGA hybrid NPs
have exhibited great potentials as a delivery system for
cancer drugs, antigens, as well as in vivo imaging agents.
They may play an important role in overcoming the
increasingly prevalent multidrug resistance (MDR) [8].pen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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core and the lipid layer allows the release of drugs in a
stepwise manner, resulting in improved therapeutic
index with reduced toxicity [9]. In vaccine application,
vaccines delivered by hybrid NPs demonstrated an en-
hanced immunogenicity [10]. Antigens can be either
conjugated on the surface of the lipid layer, or encap-
sulated inside the PLGA core, or both. In addition,
molecular adjuvants such as monophosphoryl lipid A
(MPLA) and CpG oligodeoxynucleotides (CpG OND)
can be co-delivered with antigens to further enhance
immune response and reduce systemic toxicity [11].
Despite the broad applications of lipid-PLGA NPs, some
fundamental questions have not been well addressed.
Among them, the surface chemistry of the hybrid NPs that
is governed by lipid composition and concentration,
including surface charge, hydrophobicity, fluidity, per-
meability, and steric shielding effect of polyethylene
glycol (PEG) [12], could greatly impact the performance of
the NPs as a delivery vehicle. The understanding of how a
lipid shell affects the efficacy of drug or antigen delivery
may provide basis for a more rational design of hybrid
NPs. Therefore, in this study, lipid-PLGA NPs, which are
composed of a PLGA core and a lipid shell with variable
lipid compositions, were prepared. In order to evaluate
the performance of the hybrid NPs as an antigen delivery
system, a model antigen, keyhole limpet hemocyanin
(KLH), was enclosed inside the PLGA core. The influence
of different lipid compositions on the surface charge, size,
and stability of hybrid NPs was evaluated. Furthermore,
the release of KLH from the hybrid NPs in phosphate-
buffered saline (PBS), fetal bovine serum (FBS), and hu-
man serum was studied. The in vitro uptake of the hybrid
NPs with different surface properties by dendritic cells
(DCs) was also studied. It was found that lipid shells made
from cationic lipids could improve the stability of NPs, en-
able more controlled release of antigen, and enhance the
uptake of the NPs by DCs. These results should provide
guidance to future design of hybrid NPs for improving
drug or antigen delivery.
Methods
Materials
Lactel® 50:50 PLGA was purchased from DURECT Cor-




N-[amino(polyethylene glycol)-2000] (ammonium salt)
(DSPE-PEG2000), and 1,2-diphytanoyl-sn-glycero-3-
phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-
4-yl) (ammonium salt) (NBD PE), were purchased from
Avanti Polar Lipids, Inc. (Avanti Polar Lipids, Inc.,
Alabaster, AL, USA). KLH, poly(vinyl alcohol) (PVA;Mw 89,000 to 98,000), dichloromethane, rhodamine
B, sodium deoxycholate (DOC), trichloroacetic acid
(TCA), sodium dodecyl sulfate (SDS), paraformaldehyde,
and Triton™ X-100 were purchased from Sigma-Aldrich
Inc. (Sigma-Aldrich Inc., Saint Louis, MO, USA). 1-Ethyl-
3-[3-dimethylaminopropyl] carbodiimide hydrochloride
(EDC) was purchased from Thermo Fisher Scientific
Inc. (Thermo Fisher Scientific Inc., Waltham, MA,
USA). JAWSII (ATCC® CRL-11904™) immature DCs
were purchased from ATCC (Manassas, VA, USA).
FBS, granulocyte-macrophage colony-stimulating factor
(GM-CSF) recombinant mouse protein, minimum essen-
tial medium (MEM) α, trypsin/ethylenediaminetetraacetic
acid (EDTA), and HCS CellMask™ Blue Stain were purchased
from Life Technologies Corporation (Life Technologies
Corporation, Grand Island, NY, USA).Fabrication of PLGA-KLH (PK) nanocomplex
PLGA-KLH nanocomplex was prepared using double
emulsion solvent evaporation method [13]. Briefly, PLGA
of 200 mg was dissolved in 5 mL dichloromethane,
followed by mixing with 300 μL of 10 mg/mL KLH using
a vortex mixer for 2 min. The resulting mixture emulsified
via sonication at 20% amplitude for 20 s using a sonic
dismembrator (Model 500; Fisher Scientific, Pittsburgh,
PA, USA). The primary emulsion was added dropwise into
200 mL 1% (w/v) PVA and stirred for 10 min at 500 rpm.
The above suspension was emulsified through sonication
at 50% amplitude for 120 s. The secondary emulsion was
stirred overnight to allow organic solvent to evaporate.
After settling at room temperature for 30 min, precipitant
was removed. NPs in suspension were collected by centri-
fuge at 20,000 g, 4°C for 30 min (Beckman Coulter Avanti
J-251, Brea, CA, USA). Pellet was washed using ultrapure
water for three times. The final suspension was freeze
dried (LABCONCO FreeZone 4.5, Kansas City, MO, USA)
and stored at 2°C for later use.Assembly of liposome-PK (LPK) nanocomplex
Lipid film of 20 mg with various lipid compositions was
hydrated with 15 mL hydration buffer (0.9% saline, 5%
dextrose, and 10% sucrose). After vigorous mixing with
vortex for 2 min, the resulting solution was incubated
in a 55°C water bath for 5 min and cooled to room
temperature. PK NPs of 200 mg were added into liposome
solution and pre-homogenized for 15 min using Branson
2510 bath sonicator (Branson Ultrasonics Corporation,
Danbury, CT, USA), followed by sonication in ice bath at
15% amplitude for 5 min (pulse on 20 s, pulse off 50 s)
using a sonic dismembrator (Model 500; Fisher Scientific,
Pittsburgh, PA). The formed LPK NPs were collected by
centrifuge at 20,000 g, 4°C for 30 min and stored at 2°C
after being lyophilized.
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Ten milligrams of EDC dissolved in 700 μL ultrapure
water (pH 6.8) was mixed with 300 μL of 2 mg/mL
rhodamine B. After incubation at 0°C for 10 min, the mix-
ture was added with 10 mg KLH (10 mg/mL) and stirred
in darkness at room temperature for 12 h. Fluorescently
labeled KLH was purified using Microcon centrifugal
filter units (50,000 MWCO) from EMD Millipore
(EMD Millipore, Billerica, MA, USA) and stored at 2°C
after freeze dry.
Physicochemical property characterization of NPs
Five milligrams of NPs was dispersed in 20 mL ultrapure
water (pH 7.0) using a water bath sonicator for 5 min.
Each sample was diluted by ten folds using ultrapure
water. Particle size (diameter, nm) and surface charge (zeta
potential, mV) were measured using a Malvern Nano-ZS
zetasizer (Malvern Instruments Ltd, Worcestershire, UK)
at room temperature.
Imaging of NPs using a transmission electrical microscope
(TEM)
NPs suspended in ultrapure water (5 mg/mL) were
dropped onto a 300-mesh Formvar (Agar Scientific, Essex,
UK)-coated copper grid. After 10 min standing, the
remaining suspension was carefully removed with
wipes, and the samples were negatively stained using
fresh 1% phosphotunstic acid for 60 s and washed by
ultrapure water twice. The dried samples were imaged
on a JEOL JEM 1400 Transmission Electron Microscope
(JEOL Ltd., Tokyo, Japan).
Confocal imaging of LPK NPs
Fluorescent LPK NPs were formed using the above-
described methods, except that KLH were labeled with
rhodamine B and 0.5 mg of NBD PE was added into
existing lipids (DOPC:DSPE-PEG = 16 mg:4 mg). One
hundred microliters of NP suspension (1 mg/mL) was
placed onto a glass slide and covered with a cover glass
(thickness 0.16 to 0.19 mm) from Fisher Scientific
(Pittsburgh, PA). The sample was imaged using a Zeiss
LSM 510 Laser Scanning Microscope (LSM) (Carl Zeiss,
Oberkochen, Germany).
In vitro stability of NPs
Twenty milligrams of NPs was suspended in 20 mL 10%
(v/v) human serum (pH 7.4), 10% (v/v) FBS, and 10 mM
PBS, respectively. The suspensions were constantly
mixed on a shaker at room temperature for 9 days. One
hundred fifty microliter samples were diluted in 2 mL
ultrapure water at different time points, and the particle
size was measured by Malvern Nano-ZS zetasizer. The
measurements were performed in triplicate at room
temperature.Determination of KLH content in NPs
KLH in NPs was quantified using a modified method [14].
Briefly, 10 mg of NPs was dissolved in 1 mL of 0.1 M
NaOH solution and incubated at 2°C for 12 h. The solution
pH was adjusted to 7.0 using 1 M HCl. Two hundred mi-
croliters of DOC (0.15, w/v) was added and the final volume
was adjust to 2 mL using ultrapure water. After sitting at
room temperature for 15 min, the mixture was added with
200 μL of TCA (80%, w/v) and incubated for 5 min. Sam-
ples were vortexed for 2 min and centrifuged at 5,000 g for
20 min at room temperature. Pellets were dissolved in
500 μL of SDS (5%, w/v) containing 0.01 M NaOH. Follow-
ing the protocol from the supplier, KLH concentration was
determined using Micro BCA Protein Assay Kit (Thermo
Fisher Scientific Inc., Waltham, MA, USA).
In vitro release of KLH from NPs in human plasma
Five milligrams of NPs containing rhodamine B-labeled
KLH was suspended in 1 mL of 10% (v/v) human serum
(pH 7.4) and incubated in darkness (covered by foil) at
37°C. Samples were centrifuged at 10,000 g for 15 min at
determined time points. The supernatant (200 μL) was
added into a blank 96-well plate (Thermo Fisher Scientific
Inc., Waltham, MA, USA) and measured using Synergy
HT Multi-Mode Microplate Reader (BioTek Instruments,
Inc., Winooski, VT, USA) with excitation at 530 nm and
emission at 590 nm. The pellets were resuspended in
1 mL of 10% (v/v) human serum. Release of KLH at cer-
tain time points was calculated by using the following
equation: KLH release% = Absorbance at certain time
point/Total absorbance × 100.
Flow cytometry measurement of endocytosis of NPs by
DCs
JAWSII (ATCC® CRL-11904™) immature DCs from ATCC
were cultured with alpha MEM (80%v) including ribo-
nucleosides, deoxyribonucleosides, 4 mM L-glutamine,
1 mM sodium pyruvate and 5 ng/mL murine GM-CSF,
and FBS (20%v) at 37°C, 5% CO2 in 24-well plates
(CORNING, Tewksbury, MA, USA). NPs were assem-
bled according to the above-mentioned method, ex-
cept that KLH was labeled with rhodamine B and
0.5 mg of NBD PE was added to existing lipids. One
milligram of NPs suspended in 2 mL complete
medium with a final concentration of 0.5 mg/mL was
added into each well containing 106 cells and incu-
bated for 1, 2, and 3 h, respectively. After incubation,
the medium was immediately removed and cells were
washed with ultrapure water for five times. Cells were
detached from culture plate using trypsin/EDTA solu-
tion and centrifuged at 200 g for 10 min, and cell
pellets were resuspended in 10 mM PBS (pH 7.4). Cell
samples were immediately analyzed using flow cytometer
(BD FACSAriaI, BD, Franklin Lakes, NJ, USA).
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Cells were cultured in a four-well chamber slide (Thermo
Fisher Scientific Inc., Waltham, MA, USA) using the same
method described above. NPs (0.1 mg) suspended in
500 μL complete medium with a final concentration of
0.2 mg/mL were incubated with 105 cells for certain times
(1, 2, and 3 h) at 37°C, 5% CO2. After incubation, medium
was immediately removed and cells were washed with
ultrapure water for five times. Freshly prepared 4% (w/v)
paraformaldehyde (500 μL) was added into each well, and
cells were fixed for 15 min and washed three times using
PBS (10 mM, pH 7.4). Fixed cells were permeabilized using
500 μL of 0.1% (v/v) Triton™ X-100 for 15 min at room
temperature and washed three times using PBS (10 mM,
pH 7.4). Cells were stained using 500 μL of freshly diluted
1X HCS CellMask™ Blue Stain for 15 min and washed three
times using PBS (10 mM, pH 7.4). Cell samples were covered
with a glass cover and sealed by nail polish. Images were ac-
quired using a Zeiss LSM 510 Laser Scanning Microscope
(Carl Zeiss, Germany). Each step was carried out in darkness
as much as possible to avoid fluorescence quenching.Statistical analysis
All experiments were performed in at least triplicate.
Results were expressed as mean ± standard deviation.Figure 1 Schematic illustration and TEM images of the NPs. (A) Schem
(C) TEM image of PK NPs, which highlights the uniform size and spherical
the lipid-bilayer-enclosed PK NPs. The scale bars represent 200 nm.Different treatment groups in stability test were com-
pared by one-way ANOVA following Tukey test using the
JMP pro 10 (SAS, Cary, NC, USA). Differences were con-
sidered significant at p values that were less than or equal
to 0.05.Results and discussion
Characterization of PK NPs and LPK NPs
PK NPs (schematically illustrated in Figure 1A) were
prepared through double emulsion and evaporation tech-
nique, and LPK NPs (schematically illustrated in Figure 1B)
were generated from sonication-aided fusion of PK NPs
into liposomes. The physicochemical properties, including
particle size, polydispersity, surface charge, and antigen
content of the NPs, were characterized. In PK NP prepar-
ation, 3 mg of KLH was added into 200 mg PLGA during
the primary emulsion, and the results indicated that around
75% of the KLH was entrapped inside PLGA. The KLH
contents in LPK NPs were slightly less (Table 1), and the
decrease is possibly due to the extra weight from the
liposome and loss of KLH during LPK NP preparation.
Table 1 also shows that PK NPs have a size of 191.0 ±
15.3 nm, while all LPK NPs, ranging from 208 ± 12.0 to
232 ± 34.5 nm, are slightly bigger. Such an increase in size
is probably caused by the addition of a lipid layer on theatic illustration of PK NPs. (B) Schematic illustration of LPK NPs.
shape of PK NPs. (D) TEM image of hybrid LPK NPs, which shows
Table 1 Components, physicochemical properties, and KLH content of various NPs
Group Components of NPs (mg) Size (dm. nm) Polydispersity Zeta potential (mV) KLH content (%)
PLGA KLH DOTAP DOPC DSPE-PEG
PK 200 3 0 0 0 191.0 ± 15.3 0.199 ± 0.012 −9.7 ± 1.1 1.12 ± 0.21
LPK++ 200 3 16 0 4 213 ± 38.7 0.231 ± 0.022 13.9 ± 1.3 1.11 ± 0.22
LPK− 200 3 2 14 4 232.4 ± 34.5 0.248 ± 0.018 −3.6 ± 1.4 1.05 ± 0.10
LPK+ 200 3 14 2 4 222.6 ± 21.0 0.240 ± 0.019 6.4 ± 1.1 0.92 ± 0.15
LPK−− 200 3 0 16 4 208.0 ± 12.0 0.219 ± 0.023 −5.5 ± 0.9 0.84 ± 0.03
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smaller than 500 nm, a size that has been shown to enable
the NPs to be efficiently uptaken by DCs for vaccine
applications [16]. The low polydispersity value (lower
than or equal to 0.240 ± 0.019) for each NP indicates
that the size distributions of all NPs are in a very nar-
row range, reflecting high effectiveness and robustness
of the preparation method. The surface charge of LPK
NPs expressed as zeta potential is largely dependent on
the composition of the lipid layer. PK NPs with
carboxyl groups on the surface showed the lowest zeta
potential (−9.7 ± 1.1 mV) among all NPs. Compared to
PK NPs, LPK−− NPs exhibited positively shifted zeta
potential, which might be attributed to the shielding
effect of DSPE-PEG (2000) and the small amount of
amine groups on PEG molecules [17]. The positive zeta
potentials of LPK++ and LPK+ NPs are probably attrib-
uted to the positive charges carried by DOTAP. The
results from zeta potential measurement demonstrated
that the surface charges of hybrid NPs can be flexibly
controlled by modulating the lipid composition.
Incorporation of long-chain PEG molecules on the
surface of NPs is of significant importance as they can
not only protect NPs from degradation by enzymes dur-
ing in vivo circulation [18], increasing the stability of
NPs and prolonging circulation time [19], but also allow
the inclusion of reactive groups in PEG molecules to
offer flexible conjugation of various antigens [20]. For
targeted delivery purposes, antibodies or affinity ligandsFigure 2 Confocal images of LPK NPs. The images illustrate that KLH wa
(green), confirming that PK NPs were enclosed by liposome. Scale bars repagainst receptors of target cells or tissues may be conju-
gated to the surface of NPs via PEG chains [21,22].
The morphology of NPs was studied using TEM. Con-
sistent with the particle size measured using dynamic
light scattering (DLS) (Table 1), both PK NPs (Figure 1C)
and LPK NPs (Figure 1D) displayed a highly uniform
particle size (around 200 nm) and narrow size distribu-
tion. Most of the NPs showed a smooth surface and
were of a spherical shape. Compared to PK NPs, there is
a gray membrane covering LPK NPs (Figure 1D),
demonstrating the successful hybridization of PK NPs
and liposomes. The thickness of the membrane is
around 20 nm, which is equal to the thickness of a lipid
bilayer [15].
To further confirm that PK NPs were successfully
hybridized with lipids, LPK NPs comprising PK NPs (KLH
was labeled with rhodamine B (red color)) and lipid
layers (lipids were labeled with nitro-2-1,3-benzoxadiazole
(NBD) (green color)) were examined using confocal LSM.
Figure 2 shows that the hybrid NPs are marked with both
red and green fluorescence, confirming that there is a lipid
membrane layer on the surface of PK NPs. It is worth not-
ing that the majority of NPs are double-color labeled,
indicating the high efficiency of sonication-induced
hybridization of PLGA NPs and liposomes.
Stability of NPs in PBS, FBS, and human serum
For vaccines, having a desirable stability could ensure
prolonged circulation in blood and sustained inductions labeled with rhodamine B (red) and liposome was labeled with NBD
resent 10 μm.
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lutions, (a) 10 mM PBS, (b) 10% (v/v) FBS, and (c) 10%
(v/v) human serum, was evaluated by DLS (Figure 3). All
the NPs, especially LPK NPs, were highly stable during
incubation in 10 mM PBS (Figure 3A): no significant
size change of LPK NPs was detected over 8 days of test;Figure 3 In vitro stability of NPs. Size stability of NPs in various solutions: (
of all NPs, except PK NPs, were stable in PBS over 9 days of incubation. LPK N
solutions. In both FBS and human serum, sizes of all NPs increase more quickl
within 10 h of incubation. Double asterisks indicate that the size of NPs at thisthe size of PK NPs did not increase until day 7. In both
FBS (Figure 3B) and human serum (Figure 3C), a
marked size change was detected for PK NPs after 4 h of
incubation. In contrast, all the LPK NPs stayed stable for
at least 2 days in both FBS and human serum. Especially
LPK++ NPs kept a constant size in FBS for 7 days and inA) 10 mM PBS, (B) 10% (v/v) FBS, and (C) 10% (v/v) human serum. Sizes
Ps demonstrated superior stability compared to PK NPs in the three
y compared to that in PBS. The inserts show antigen release from NPs
point was significantly higher compared to that at 0 h (p value <0.05).
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LPK NPs appears to be related to lipid compositions;
NPs with more positive charges exhibited higher stability
compared to those with less positive charges. Higher sta-
bility of positively charged hybrid NPs may have resulted
from a strong electrostatic attraction between cationic
lipid layer and anionic PLGA core [22,23].
In vitro release of antigen from NPs
The evaluation of in vitro antigen release from NPs in
human serum could simulate the antigen release in vivo.
In agreement with other reports that a lipid shell could
help retain molecules loaded inside PLGA cores [15], in
this work, LPK NPs displayed more controlled and de-
layed release of the payload, KLH. As shown in Figure 4,
a burst release was observed between 10 and 12 h for
PK NPs, and more than 70% of KLH was released in the
first 16 h. In contrast, more than 50% of the KLH was
released between 16 and 96 h for LPK NPs, and in par-
ticular, only 35% and 37% percent of KLH were released
in the first 16 h for LPK++ and LPK+ NPs, respectively.
The regulated release of KLH in LPK NPs is probably
due to the presence of a lipid bilayer that acts as a
barrier to reduce KLH diffusion from the PLGA core to
the bulk solution and the PEG shield that delays the
enzymatic degradation of NPs [24]. Consistent with the
results from size stability study, antigen release from
NPs with more positive surface charges was slower than
the release from NPs with less positive charges. The
slower antigen release may be attributed to the tighterFigure 4 Release of KLH contained in NPs in 10% human serum (pH 7
showed a burst release of KLH between 8 and 10 h. LPK displayed a delaye
between 16 and 24 h. The extent of release was also dependent on the coassociation of the lipid layer with the PLGA core,
which reduces the diffusion of KLH from NPs into the
bulk solution. Delayed antigen release from NPs may
reduce loss of antigen during circulation and increase
bioavailability of antigen to DCs, thereby enhancing
immune response.
Endocytosis of NPs by DCs
DC is the most professional antigen-presenting cell that
can initiate and regulate adaptive immune response
[25,26]. Higher internalization efficiency of NPs by DCs
may lead to more activated T helper cells, resulting in
enhanced immune response. Fluorescently marked NPs
were added into immature DCs from mouse to study the
uptake of NPs by DCs. Results from flow cytometry
measurement (Figure 5) showed that higher internaliza-
tion efficiency was observed in all LPK NPs compared to
PK NPs. In the first hour after NP treatment, only 28%
of DCs had taken up PK NPs while 77%, 63%, 39%,
and 50% of DCs had taken up LPK++, LPK+, LPK−−, and
LPK− NPs, respectively. After 3 h of incubation, more
than 90% of DCs have internalized LPK NPs in all four
groups; however, only 52% of DCs have taken up PK
NPs. Evidently, surface charge has a great impact on NP
uptake. For example, 77% of DCs ingested LPK++ NPs in
the first hour of incubation, but only 39% for LPK−−
NPs. Faster uptake of NPs by DCs is important because it
should reduce the clearance of NPs by reticuloendothelial
system (RES), avoid premature degradation by enzymes,
and increase the availability of antigens to the immune.4) at 37°C. All NPs exhibited a prolonged release of KLH. PK NPs
d release profile, in which the largest percentage release occurred
mposition and charge of the NPs.
Figure 5 Flow cytometry measurement of uptake of PK NPs and LPK NPs by JAWSII DCs. One milligram of NPs was incubated with 106 cells
for 1, 2, and 3 h, respectively. As time lapsed, more NPs were ingested by cells. Enhanced uptake of LPK NPs by DCs was observed compared to
PK NPs. DCs are more readily to uptake positively charged NPs compared to negatively charged NPs. Most of the cells (>90%) had taken up LPK
NPs in 3 h, while only 52% of the cells had taken up PK NPs.
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NPs had superior uptake efficiency in comparison to
PK NPs. In the first hour after NP treatment, only few PK
NPs were internalized by DCs; in contrast, both LPK++
and LPK−− NPs with large quantities were taken up
by DCs (Figure 6A). After 2 h, the internalized PK
NPs were located in a small area of the cell, while
LPK NPs were widely distributed in cells (Figure 6B).
Faster uptake of LPK NPs by DCs is probably due to
the coating lipid bilayer that could mimic the cell mem-
brane to fuse with the plasma membrane of DCs. Con-
sistent with the results from flow cytometry study,
more LPK++ NPs were ingested by DCs than LPK−−
NPs within the same period of time, suggesting that
DCs could more efficiently capture NPs with more
positive surface charges. The faster uptake of LPK++NPs may be due to the electrostatic attraction between
the positive surface charges on LPK++ and the negative
charges on the plasma membrane of DCs.
Conclusions
In summary, lipid-PLGA hybrid NPs with variable lipid
compositions were constructed. As a potential antigen
delivery system, lipid-PLGA NPs exhibited superior
quality in comparison to PLGA NPs in terms of stability,
antigen release, and particle uptake by DCs. The in vitro
performance of lipid-PLGA NPs was highly influenced
by the composition of the lipid layer, which dictates the
surface chemistry of hybrid NPs. Hybrid NPs enveloped
by lipids with more positive surface charges demon-
strated higher stability, better controlled release of anti-
gen, and more efficient uptake by DCs than particles
Figure 6 (See legend on next page.)
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Figure 6 Confocal images of internalization of PK NPs and LPK NPs by JAWSII DCs. One hundred thousand cells were incubated with
0.1 mg NPs for 1 h (A), 2 h (B), and 3 h (C), respectively. The incubation concentration was 0.2 mg/mL. Red color is from rhodamine B, which
was used to label KLH; green color is from NBD PE, which is a fluorescent lipid used to label the lipid layer; and blue color is from CellMask™
Blue Stain, which was used to label the cell membrane. Both positively charged LPK NPs and negatively charged LPK NPs were internalized
more readily by cells than PK NPs. Scale bars represent 5 μm.
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provide basis for future design of lipid-PLGA hybrid
NPs intended for antigen delivery.
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